Dallas, Texas 11/18/2013 (Financialstrend) – Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) issued its quarterly-earnings report on Thursday. It reported an earnings per share of 0.07 for the quarter which was on par with the average analyst estimate of $0.07.
Recently, numerous research firms have weighed on the Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) stock. Aegis’s analysts have upped their PT on Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) shares from $4.00 to $5.50 on 21 October and have now set a “buy” rating on the company stock. Zacks analysts upgraded Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) shares from a “neutral” to an “outperform” rating on 18 October and have now set a PT of $3.10 on the stock.
Friday’s trading
In Friday’s trading session, Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) rose by 13.48%. The shares opened at a price of $1.43, which touched the intraday high of $1.65 and headed to a close of $1.60. Around 1.46 million exchanged hands over the trading day and an average volume of 2.30 million shares were traded over a 30 day period. The 52-week low of Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) shares is $0.40 and its 52-week high is $3.65. The company has a market capitalization of $84.63 million.
About the company
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage bio- pharmaceutical company. It focuses on developing & commercializing prescription drugs that target addiction diseases & disorders of the central-nervous system with a primary focus on treatment of addiction &epilepsy. As of 31 December 2011, it had 2drugs in development: CPP-109 & CPP-115. As of 31 December 2011, Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) was evaluating the company’s drug candidate, CPP-109 in the treatment of cocaine-addiction. As of 31 December 2011, it was in the earl-stages of developing CPP-115. This is one more GABA aminotransferase-inhibitor. It has identified 2 market-opportunities that can be exploited by pharmacotherapies. These inhibit GABA-aminotransferase (GABA-AT): drug addiction & epilepsy.